Multipurpose Applied Physics Lattice Experiment

Last updated

MAPLE, short for the Multipurpose Applied Physics Lattice Experiment, later renamed MDS Medical Isotope Reactors (MMIR), was a dedicated isotope-production facility built by AECL and MDS Nordion. It included two identical reactors, I and II, as well as the isotope-processing facilities necessary to produce a large portion of the world's medical isotopes, especially molybdenum-99, medical cobalt-60, xenon-133, iodine-131 and iodine-125. [1]

Contents

An operational license for the MAPLE I reactor was granted in 1999, and the reactor went critical for the first time in early 2000. MAPLE II followed in the fall of 2003. Problems with the reactors during the testing period, most notably an unexpected positive power co-efficient of reactivity, led to the cancellation of the project in 2008 and the shutdown of both reactors.

History

Background

With the completion of the NRX reactor in 1947, AECL's Chalk River Laboratories possessed the world's most powerful research reactor. While the large neutron fluxes available in the reactor led to advances in such fields as condensed matter physics and neutron spectroscopy, many experiments were carried out involving the production of new isotopes. The field of nuclear medicine developed when it was realized that some of these artificially created isotopes could be used to diagnose and treat many diseases, especially cancers.

Pioneering medical work done in the late 1940s and early 1950s established cobalt-60 as a useful isotope, as the relatively high-energy gamma rays produced when it undergoes beta decay are able to penetrate the skin of the patient, and deliver a greater portion of the dose directly to the tumor. The high neutron efficiency of the NRX's heavy water-moderated design, coupled with the high neutron flux of the reactor, made it relatively inexpensive for AECL to produce medical-grade cobalt-60. For example, the cost of the entire unit used to perform the first cobalt-60 treatment was about $50,000. By way of contrast, it would cost $50,000,000 just to produce enough radium (which had been previously used as a therapy source) to perform the same procedure. [2]

With this promising start, AECL came to be a major world supplier of medical isotopes, using both the NRX reactor, and the NRU reactor, which came on-line in 1957. However, as these reactors began to age, it became clear that a new facility would be needed to continue the production of medical isotopes.

Beginnings

In the late 1980s, AECL began to acknowledge that continued isotope production would require the construction of a new reactor to replace capacity lost by the planned closing of the NRX in 1992, and the planned closing of the NRU early in the new millennium. Design work on a replacement, originally under the name "Maple-X10", began in the late 1980s. [3]

As part of a restructuring taking place around the same time, the medical isotopes side of AECL was reorganized as Nordion in 1988. Work on the X10 project essentially ended at this point. Nordion company was purchased by MDS in 1991, and an agreement was reached between AECL and MDS Nordion that a new facility dedicated to the production of medical isotopes would be needed. [3] A formal agreement was signed to begin the project in August 1996. Following a year-long environmental assessment, construction began in December 1997. [4]

The design that resulted involved a facility with two identical reactors, each capable of supplying 100% of the world's medical isotope demand. The second reactor would function primarily as a backup, to ensure that the supply of isotopes would not be interrupted by maintenance or unplanned shutdowns. This is made necessary by the nature of medical isotopes; many have short half-lives, and must be used within a few days of production. With treatments being constantly carried out around the globe, an uninterruptible supply was essential.

There had been some local opposition to the use of highly enriched uranium (HEU) in the reactor, [5] as well as from activists in the United States who fear that the uranium could be stolen by terrorists and used to fabricate a bomb. [6]

Current status

Originally planned to complete construction in 1999 and 2000, both reactors were instead completed in May 2000. An operational license was granted in August 1999 for the MAPLE I reactor, and extended to include the MAPLE II reactor in June 2000. Commissioning testing was begun immediately, with the MAPLE I achieving its first sustained reaction in February 2000, and MAPLE II following in October 2003.

However, during testing, it was noted that some of the emergency shut-off rods in the MAPLE I reactor could fail to deploy in certain demanding situations. This failure was ascribed to workmanship and design issues, and related to fine metal particles accumulating in the control rods' housing and interfering with their free movement.[ citation needed ]

In addition, later testing found that the reactors have a positive power co-efficient of reactivity (PCR), which was in disagreement with the prediction of the modelling, and was a significant barrier to commissioning. [3] A positive power co-efficient means that the reactor becomes more reactive when it heats up; in the case of an unplanned power spike, such a design can "run away" and potentially cause a meltdown. [7]

Consequently, significant efforts were made to resolve the outstanding issues, but progress towards commissioning the reactors was markedly slowed. [8] [9] During the subsequent eight-year-long delay in the start of commercial production, the project significantly overran its budgeted cost. The original budget was $140 million, but by 2005 it had already cost $300 million. [3] Disputes over responsibility for the overruns between AECL and MDS Nordion added a further layer of complexity to the process. After considerable negotiation, AECL assumed full responsibility for the reactor in a settlement. [10]

The MAPLE facility was granted an extension on its operating license on 25 October 2007, which would permit operations until 31 October 2011. [11] This (final) submission envisioned that the MAPLE I reactor would be operational in late 2008. [12]

On 16 May 2008, AECL released a statement announcing that the MAPLE program had been terminated, as it had become "no longer feasible to complete the commissioning and start-up of the reactors". [7] In this statement, AECL indicated that they would move to further extend the licence of the operating NRU reactor to continue the production of medical isotopes. The statement left unclear what long-term direction AECL would take for its medical isotope production business.

Related Research Articles

Enriched uranium is a type of uranium in which the percent composition of uranium-235 has been increased through the process of isotope separation. Naturally-occurring uranium is composed of three major isotopes: uranium-238, uranium-235, and uranium-234. 235U is the only nuclide existing in nature that is fissile with thermal neutrons.

NRX was a heavy-water-moderated, light-water-cooled, nuclear research reactor at the Canadian Chalk River Laboratories, which came into operation in 1947 at a design power rating of 10 MW (thermal), increasing to 42 MW by 1954. At the time of its construction, it was Canada's most expensive science facility and the world's most powerful nuclear research reactor. NRX was remarkable both in terms of its heat output and the number of free neutrons it generated. When a nuclear reactor such as NRX is operating, its nuclear chain reaction generates many free neutrons. In the late 1940s, NRX was the most intense neutron source in the world.

<span class="mw-page-title-main">Chalk River Laboratories</span> Nuclear research facility located near Chalk River, Canada

Chalk River Laboratories is a Canadian nuclear research facility in Deep River, about 180 km (110 mi) north-west of Ottawa.

Atomic Energy of Canada Limited (AECL) is a Canadian federal Crown corporation and Canada's largest nuclear science and technology laboratory. AECL developed the CANDU reactor technology starting in the 1950s, and in October 2011 licensed this technology to Candu Energy.

<span class="mw-page-title-main">Bruce Nuclear Generating Station</span> Nuclear power station in Ontario, Canada. Largest nuclear power station in Canada

Bruce Nuclear Generating Station is a nuclear power station located on the eastern shore of Lake Huron in Ontario, Canada. It occupies 932 ha of land. The facility derives its name from Bruce Township, the local municipality when the plant was constructed, now Kincardine due to amalgamation. With eight CANDU pressurized heavy-water reactors, it was the world's largest fully operational nuclear generating station by total reactor count and the number of currently operational reactors until 2016, when it was exceeded in nameplate capacity by South Korea's Kori Nuclear Power Plant. The station is the largest employer in Bruce County, with over 4000 workers.

Nordion Inc., a Sotera Health company, is a health science company that provides Cobalt-60 used for sterilization and treatment of disease (radiotherapy).

<span class="mw-page-title-main">Petten nuclear reactor</span> Research reactor in Petten, Netherlands

The Petten High Flux Reactor (HFR) is a nuclear research reactor located in Petten, Netherlands. The HFR is on the premises of the Petten research centre and it is a high flux reactor. It is owned by the Joint Research Centre (JRC) and managed by the Nuclear Research and Consultancy Group (NRG).

<span class="mw-page-title-main">Clinton Power Station</span> Nuclear power plant in DeWitt County, Illinois

The Clinton Power Station is a nuclear power plant located near Clinton, Illinois, USA. The power station began commercial operation on November 24, 1987 and has a nominal net electric output of 1062 MWe. Due to inflation and cost overruns, Clinton's final construction cost was $4.25 billion, nearly 1,000% over the original budget of $430 million and seven years behind schedule.

<span class="mw-page-title-main">ZEEP</span> Historic Canadian nuclear reactor for the production of plutonium

The ZEEP reactor was a nuclear reactor built at the Chalk River Laboratories near Chalk River, Ontario, Canada. ZEEP first went critical at 15:45 on September 5, 1945. ZEEP was the first operational nuclear reactor outside the United States.

<span class="mw-page-title-main">Research reactor</span> Nuclear device not intended for power or weapons

Research reactors are nuclear fission-based nuclear reactors that serve primarily as a neutron source. They are also called non-power reactors, in contrast to power reactors that are used for electricity production, heat generation, or maritime propulsion.

The National Research Universal (NRU) reactor was a 135 MW nuclear research reactor built in the Chalk River Laboratories, Ontario, one of Canada’s national science facilities. It was a multipurpose science facility that served three main roles. It generated radionuclides used to treat or diagnose over 20 million people in 80 countries every year. It was the neutron source for the NRC Canadian Neutron Beam Centre: a materials research centre that grew from the Nobel Prize-winning work of Bertram Brockhouse. It was the test bed for Atomic Energy of Canada Limited to develop fuels and materials for the CANDU reactor. At the time of its retirement on March 31, 2018, it was the world's oldest operating nuclear reactor.

<span class="mw-page-title-main">SLOWPOKE reactor</span> Family of nuclear research reactors

The SLOWPOKE is a family of low-energy, tank-in-pool type nuclear research reactors designed by Atomic Energy of Canada Limited (AECL) beginning in the late 1960s. John W. Hilborn is the scientist most closely associated with their design. They are beryllium-reflected with a very low critical mass, but provide neutron fluxes higher than available from a small particle accelerator or other radioactive sources.

<span class="mw-page-title-main">Swimming pool reactor</span> Type of nuclear reactor

A swimming pool reactor, also called an open pool reactor, is a type of nuclear reactor that has a core immersed in an open pool usually of water.

Iodine-125 (125I) is a radioisotope of iodine which has uses in biological assays, nuclear medicine imaging and in radiation therapy as brachytherapy to treat a number of conditions, including prostate cancer, uveal melanomas, and brain tumors. It is the second longest-lived radioisotope of iodine, after iodine-129.

The Whiteshell Reactor No. 1, or WR-1, was a Canadian research reactor located at AECL's Whiteshell Laboratories (WNRL) in Manitoba. Originally known as Organic-Cooled Deuterium-Reactor Experiment (OCDRE), it was built to test the concept of a CANDU-type reactor that replaced the heavy water coolant with an oil substance. This had a number of potential advantages in terms of cost and efficiency.

<span class="mw-page-title-main">Technetium-99m</span> Metastable nuclear isomer of technetium-99

Technetium-99m (99mTc) is a metastable nuclear isomer of technetium-99, symbolized as 99mTc, that is used in tens of millions of medical diagnostic procedures annually, making it the most commonly used medical radioisotope in the world.

The NRC Canadian Neutron Beam Centre (CNBC) was Canada's national user facility that enabled researchers to use neutron beams as tools for world-class materials research. The CNBC was located at Chalk River Laboratories, where Atomic Energy of Canada Limited (AECL) owned and operated the National Research Universal (NRU) reactor that provided the neutrons for CNBC. CNBC was a global leader in the development of materials and products for businesses. Like most other neutron beam laboratories, the CNBC operated beamlines as a service to external researchers. In a typical year, about 250 individuals participated in research that relied on access to the suite of 6 beamlines at the CNBC.

<span class="mw-page-title-main">Nuclear industry in Canada</span>

Nuclear industry in Canada is an active business and research sector, producing about 15% of its electricity in nuclear power plants of domestic design. Canada is the world's largest exporter of uranium, and has the world's second largest proven reserves. Canada also exports nuclear technology within the terms of the Nuclear Non-proliferation Treaty, to which it is a signatory, and is the world's largest producer of radioactive medical isotopes.

<span class="mw-page-title-main">Pakistan Atomic Research Reactor</span> Pair of research nuclear reactors in Nilore, Islamabad, Pakistan

The Pakistan Atomic Research Reactor or (PARR) are two nuclear research reactors and two other experimental neutron sources located in the PINSTECH Laboratory, Nilore, Islamabad, Pakistan.

Phoenix, formerly known as Phoenix Nuclear Labs, is a company specializing in neutron generator technology located in Monona, Wisconsin. Founded in 2005, the company develops nuclear and particle accelerator technologies for application in medicine, defense and energy. Phoenix has held contracts with the U.S. Army, the U.S. Department of Energy, the U.S. Department of Defense and the U.S. Air Force. Phoenix developed a proprietary gas target neutron generator technology and has designed and built a number of particle accelerator-related technologies.

References

  1. ↑ How the MAPLE Reactors Work Archived 2008-03-22 at the Wayback Machine
  2. ↑ "CBC Archives". CBC News.
  3. 1 2 3 4 Myers, Terry (21 May 2008). "AECL scraps Maple project". North Renfrew Times. Archived from the original on 2 June 2008.
  4. ↑ "Archived copy" (PDF). anes.fiu.edu. Archived from the original (PDF) on 22 January 2004. Retrieved 22 May 2022.{{cite web}}: CS1 maint: archived copy as title (link)
  5. ↑ Website of local group opposed to HEU in MAPLE
  6. ↑ 2/19/99 Letter from American group concerned about HEU use in MAPLE
  7. 1 2 McCarthy, Shawn (17 May 2008). "AECL pulls plug on reactors after millions spent". The Globe and Mail.
  8. ↑ Press release of an agreement with INVAP for numerical modelling work Archived 2008-06-16 at the Wayback Machine
  9. ↑ Index of AECL submissions to the CNSC for licensing, and the subsequent decisions. Archived 2008-05-24 at the Wayback Machine
  10. ↑ PR Newswire report of AELC-MDS Nordion Settlement (in brief)
  11. ↑ Release confirming licence extension. Archived 2008-01-05 at the Wayback Machine
  12. ↑ October 2007 AECL submission to the CNSC, see Slide 8 on Page 4.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.